Aliases & Classifications for Cerebellar Disease

MalaCards integrated aliases for Cerebellar Disease:

Name: Cerebellar Disease 12 15
Cerebellar Diseases 45 74
Cerebellar Dysfunction 56
Cerebellar Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:2786
MeSH 45 D002526
SNOMED-CT 69 49784007
UMLS 74 C0007760

Summaries for Cerebellar Disease

MedlinePlus : 44 When you play the piano or hit a tennis ball you are activating the cerebellum. The cerebellum is the area of the brain that controls coordination and balance. Problems with the cerebellum include Cancer Genetic disorders Ataxias - failure of muscle control in the arms and legs that result in movement disorders Degeneration - disorders caused by brain cells decreasing in size or wasting away Treatment of cerebellar disorders depends on the cause. In some cases, there is no cure but treatment may help with symptoms. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Cerebellar Disease, also known as cerebellar diseases, is related to spinocerebellar ataxia 1 and spinocerebellar ataxia 6, and has symptoms including ataxia, dysarthria and cerebellar cognitive affective syndrome. An important gene associated with Cerebellar Disease is CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Myometrial Relaxation and Contraction Pathways. The drugs Mecasermin and Clonidine have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and spinal cord, and related phenotypes are no effect and behavior/neurological

Disease Ontology : 12 A brain disease that is characterized by damage to brain substance located in cerebellum; has symptom ataxia, has symptom dysarthria, and has symptom cerebellar cognitive affective syndrome.

Wikipedia : 77 The cerebellum (Latin for "little brain") is a major feature of the hindbrain of all vertebrates. ... more...

Related Diseases for Cerebellar Disease

Diseases related to Cerebellar Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 spinocerebellar ataxia 1 31.5 ATXN3 ATXN7 CACNA1A
2 spinocerebellar ataxia 6 31.5 ATXN3 ATXN7 CACNA1A
3 spinocerebellar ataxia 17 31.4 ATXN3 ATXN7 CACNA1A
4 machado-joseph disease 31.3 ATXN3 ATXN7 CACNA1A
5 spinocerebellar ataxia 14 31.1 APTX ITPR1 PRKCG
6 spinocerebellar ataxia 12 31.0 ATXN3 ATXN7 CACNA1A PPP2R2B
7 spinocerebellar ataxia 36 30.7 ATXN10 NOP56 PPP2R2B
8 spinocerebellar ataxia 31 30.7 ATXN3 ATXN7 CACNA1A PLEKHG4 SACS SETX
9 spinocerebellar ataxia 2 29.8 ATXN3 ATXN7 CACNA1A
10 friedreich ataxia 1 29.7 APTX ATXN3 CACNA1A SETX
11 autosomal dominant cerebellar ataxia 28.2 ATXN10 ATXN3 ATXN7 CACNA1A PLEKHG4 PPP2R2B
12 aceruloplasminemia 25.6 APTX ATM ATP1A3 ATP2B3 ATXN10 ATXN3
13 cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 11.6
14 leukodystrophy, demyelinating, adult-onset, autosomal dominant 11.2
15 polyglucosan body neuropathy, adult form 11.1
16 cerebellar ataxia, cayman type 11.1
17 medulloblastoma 10.9
18 cowden syndrome 1 10.9
19 spinocerebellar ataxia 10 10.9
20 leukodystrophy, hypomyelinating, 5 10.9
21 dandy-walker syndrome 10.7
22 spinocerebellar ataxia 34 10.7
23 spinocerebellar ataxia, autosomal recessive 2 10.7
24 mannosidosis, alpha b, lysosomal 10.7
25 spinocerebellar ataxia 5 10.7
26 spinocerebellar ataxia 15 10.7
27 spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1 10.7
28 spinocerebellar ataxia, autosomal recessive 4 10.7
29 spinocerebellar ataxia 19 10.7
30 spinocerebellar ataxia 23 10.7
31 spinocerebellar ataxia 28 10.7
32 spinocerebellar ataxia, autosomal recessive 8 10.7
33 spinocerebellar ataxia, autosomal recessive 10 10.7
34 spinocerebellar ataxia, autosomal recessive 12 10.7
35 spinocerebellar ataxia, autosomal recessive 13 10.7
36 spinocerebellar ataxia 38 10.7
37 spinocerebellar ataxia, autosomal recessive 18 10.7
38 spinocerebellar ataxia, autosomal recessive 20 10.7
39 spinocerebellar ataxia, autosomal recessive 21 10.7
40 spinocerebellar ataxia 43 10.7
41 spinocerebellar ataxia, autosomal recessive 25 10.7
42 spinocerebellar ataxia, autosomal recessive 26 10.7
43 spinocerebellar ataxia 44 10.7
44 spinocerebellar ataxia, autosomal recessive 24 10.7
45 spinocerebellar ataxia, autosomal recessive 23 10.7
46 spinocerebellar ataxia, autosomal recessive 22 10.7
47 spinocerebellar ataxia 42 10.7
48 spinocerebellar ataxia 41 10.7
49 spinocerebellar ataxia, autosomal recessive 17 10.7
50 spinocerebellar ataxia 40 10.7

Graphical network of the top 20 diseases related to Cerebellar Disease:



Diseases related to Cerebellar Disease

Symptoms & Phenotypes for Cerebellar Disease

Symptoms:

12
  • ataxia
  • dysarthria
  • cerebellar cognitive affective syndrome

UMLS symptoms related to Cerebellar Disease:


seizures, ataxia, tremor, back pain, pain, headache, dysdiadochokinesis, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, cerebellar ataxia, cerebellar ataxia/dyskinesia, adiadochokinesis

GenomeRNAi Phenotypes related to Cerebellar Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 APTX ATM ATP1A3 ATP2B3 ATXN10 ATXN3

MGI Mouse Phenotypes related to Cerebellar Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 ATM ATP1A3 ATXN3 ATXN7 CACNA1A CALB1
2 nervous system MP:0003631 9.36 ATM ATP1A3 ATXN3 ATXN7 CACNA1A CALB1

Drugs & Therapeutics for Cerebellar Disease

Drugs for Cerebellar Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mecasermin Approved, Investigational Phase 4 68562-41-4
2
Clonidine Approved Phase 4 4205-90-7 2803
3
Polyestradiol phosphate Approved Phase 4 28014-46-2
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
5
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
6
Metformin Approved Phase 4 657-24-9 14219 4091
7
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
8
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
9
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
10
Citalopram Approved Phase 4 59729-33-8 2771
11
Amantadine Approved Phase 4 768-94-5 2130
12 Adrenergic Agonists Phase 4
13 Estradiol 3-benzoate Phase 4
14 Adrenergic Agents Phase 4
15 Adrenergic alpha-Agonists Phase 4
16 Antihypertensive Agents Phase 4,Phase 2
17 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
19 Mitogens Phase 4
20 Contraceptive Agents Phase 4
21 Estradiol 17 beta-cypionate Phase 4
22 Sympatholytics Phase 4
23 Analgesics Phase 4,Phase 1,Phase 2
24 Insulin, Globin Zinc Phase 4
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
26 Autonomic Agents Phase 4,Phase 3,Early Phase 1,Not Applicable
27 arginine Phase 4
28 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
29 insulin Phase 4
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
31 Estrogens Phase 4
32 Adrenergic alpha-2 Receptor Agonists Phase 4
33 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 interferons Phase 4,Phase 3,Phase 2
37 Interferon-beta Phase 4
38 Adjuvants, Immunologic Phase 4
39 Hypoglycemic Agents Phase 4,Phase 3
40 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
41 Dopamine Uptake Inhibitors Phase 4
42 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Cytochrome P-450 Enzyme Inhibitors Phase 4
44 Neurotransmitter Uptake Inhibitors Phase 4
45 Serotonin Uptake Inhibitors Phase 4
46 Cholinergic Antagonists Phase 4
47 Antidepressive Agents, Second-Generation Phase 4
48 Serotonin Agents Phase 4
49 Muscarinic Antagonists Phase 4
50 Antiparkinson Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
2 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
3 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
4 An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia Completed NCT01716221 Phase 4 bupropion & Citalopram;Bupropion & Placebo;Placebo & Citalopram;Placebo & Placebo
5 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
6 An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT02889302 Phase 3 KPS-0373;Placebo
7 A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970137 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
8 A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970124 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
9 An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970111 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
10 A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970098 Phase 3 KPS-0373, High dose;KPS-0373, Low dose;Placebo
11 Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia Completed NCT02797080 Phase 3 interferon γ-1b
12 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study Completed NCT02593773 Phase 3 Interferon γ-1b
13 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Completed NCT02415127 Phase 3 Interferon γ-1b;Placebo
14 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Completed NCT02333305 Phase 3
15 Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) Completed NCT01303406 Phase 3 Idebenone;Placebo
16 Efficacy of Riluzole in Hereditary Cerebellar Ataxia Completed NCT01104649 Phase 2, Phase 3 riluzole;Placebo comparator
17 Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Completed NCT01096082 Phase 2, Phase 3 Lithium Carbonate;Placebo
18 Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) Completed NCT00993967 Phase 3 idebenone
19 A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients Completed NCT00905268 Phase 3 idebenone;Placebo
20 Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Completed NCT00811681 Phase 3 pioglitazone;Placebo
21 Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Completed NCT00697073 Phase 3 Idebenone
22 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3 Conjugated pneumococcal vaccine (Prevenar)
23 Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Completed NCT00537680 Phase 3 Idebenone;Idebenone;Placebo
24 Troriluzole in Adult Subjects With Spinocerebellar Ataxia Recruiting NCT03701399 Phase 3 troriluzole;Placebos
25 Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study Recruiting NCT03563053 Phase 3
26 Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) Recruiting NCT03347344 Phase 3 Riluzole;Placebo
27 Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy Recruiting NCT03901638 Phase 3 Tllsh2910;Placebo
28 EDS in Ataxia Telangiectasia Patients Recruiting NCT02770807 Phase 3 EDS-EP dose range of ~5-10 mg DSP/infusion;EDS-EP dose range of ~14-22 mg DSP/infusion;Placebo
29 An Open Pilot Trial of BHV-4157 Active, not recruiting NCT03408080 Phase 3 BHV-4157
30 Trial in Adult Subjects With Spinocerebellar Ataxia Active, not recruiting NCT02960893 Phase 2, Phase 3 BHV-4157;Placebo Comparator
31 Riluzole in Patients With Spinocerebellar Ataxia Type 7 Not yet recruiting NCT03660917 Phase 2, Phase 3 Riluzole;Placebo
32 Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Terminated NCT00803868 Phase 2, Phase 3 varenicline;placebo
33 Effect of Nicotinamide in Friedreich's Ataxia Unknown status NCT01589809 Phase 2 nicotinamide
34 Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia Unknown status NCT02540655 Phase 2
35 Clinical Study to Evaluate the Safety and Efficacy BMMNC in Cerebellar Ataxia Unknown status NCT01958177 Phase 1, Phase 2
36 4-Aminopyridine in Episodic Ataxia Type 2 Unknown status NCT01543750 Phase 2 4-Aminopyridine;Placebo
37 A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation Unknown status NCT01489267 Phase 2
38 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia Unknown status NCT01360164 Phase 1, Phase 2
39 Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia Completed NCT00202397 Phase 2 Riluzole
40 A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01384435 Phase 2 KPS-0373;KPS-0373;KPS-0373;KPS-0373;Placebo
41 Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease Completed NCT02147886 Phase 2 Cabaletta for IV infusion once weekly during 24 weeks;Cabaletta for IV infusion once weekly during 24 weeks
42 A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01004016 Phase 2 KPS-0373;Placebo
43 Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT00863538 Phase 2 KPS-0373
44 The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease Completed NCT02039206 Phase 2
45 Open Trail of γIFN for Friedreich Ataxia Completed NCT03888664 Phase 2 gamma interferon
46 High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration Completed NCT00034242 Phase 2 high-dose intravenous immunoglobulin (IVIG)
47 Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia Completed NCT03214588 Phase 2 TAK-831;TAK-831 Placebo
48 (+) Epicatechin to Treat Friedreich's Ataxia Completed NCT02660112 Phase 2 (+)-Epicatechin
49 A First in Human Study of RT001 in Patients With Friedreich's Ataxia Completed NCT02445794 Phase 1, Phase 2 RT001;RT001 comparator
50 A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients Completed NCT02035020 Phase 2 gamma interferon

Search NIH Clinical Center for Cerebellar Disease

Cochrane evidence based reviews: cerebellar diseases

Genetic Tests for Cerebellar Disease

Anatomical Context for Cerebellar Disease

MalaCards organs/tissues related to Cerebellar Disease:

42
Brain, Cerebellum, Spinal Cord, Eye, Liver, Testes, Cortex

The Foundational Model of Anatomy Ontology organs/tissues related to Cerebellar Disease:

20
Cerebellum; Has_symptom Ataxia

Publications for Cerebellar Disease

Articles related to Cerebellar Disease:

(show top 50) (show all 116)
# Title Authors Year
1
Extinction and Renewal of Conditioned Eyeblink Responses in Focal Cerebellar Disease. ( 30155831 )
2019
2
Vertigo in Cerebellar Disease-Do the Eyes Have It or Is There More to Perceive? ( 30539355 )
2019
3
Slow saccades in cerebellar disease. ( 30680221 )
2019
4
Can patients with cerebellar disease switch learning mechanisms to reduce their adaptation deficits? ( 30689760 )
2019
5
Epidemiology of Cerebellar Diseases and Therapeutic Approaches. ( 28940047 )
2018
6
Epigenetic cerebellar diseases. ( 29891061 )
2018
7
Neuro-ophthalmologic assessment and investigations in children and adults with cerebellar diseases. ( 29903449 )
2018
8
Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review. ( 28689294 )
2017
9
Internally Versus Externally Cued Speech in Parkinson's Disease and Cerebellar Disease. ( 28654941 )
2017
10
Cerebellar Disease Mimicking Cerebrotendinous Xanthomatosis: Langerhans Cell Histiocytosis. ( 28554492 )
2017
11
Cerebellar Disease of Ruminants. ( 28166936 )
2017
12
Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease. ( 27957507 )
2017
13
The effect of a task-specific locomotor training strategy on gait stability in patients with cerebellar disease: a feasibility study. ( 27216372 )
2017
14
A toolbox to visually explore cerebellar shape changes in cerebellar disease and dysfunction. ( 28479655 )
2016
15
Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease. ( 27307499 )
2016
16
Automated cerebellar lobule segmentation with application to cerebellar structural analysis in cerebellar disease. ( 26408861 )
2016
17
Acquired Esotropia in Cerebellar Disease: A Case Series Illustrating Misdiagnosis as Isolated Lateral Rectus Paresis and Progression Over Time. ( 27928333 )
2015
18
Assessment of postural stability in patients with cerebellar disease using gyroscope data. ( 26118512 )
2015
19
Using human induced pluripotent stem cells to model cerebellar disease: hope and hype. ( 25985846 )
2015
20
Training balance with opto-kinetic stimuli in the home: a randomized controlled feasibility study in people with pure cerebellar disease. ( 25082955 )
2015
21
Consensus paper: radiological biomarkers of cerebellar diseases. ( 25382714 )
2015
22
Neuro-ophthalmic manifestations of cerebellar disease. ( 25439294 )
2014
23
Clinical manifestations of cerebellar disease. ( 25439285 )
2014
24
Torpedo formation and Purkinje cell loss: modeling their relationship in cerebellar disease. ( 24590661 )
2014
25
Effects of balance and gait rehabilitation in cerebellar disease of vascular or degenerative origin. ( 24398721 )
2014
26
Cerebellar diseases. Preface. ( 25439298 )
2014
27
Disturbed vestibular-neck interaction in cerebellar disease. ( 23081756 )
2013
28
Effects of task constraints on obstacle avoidance strategies in patients with cerebellar disease. ( 23022155 )
2013
29
14-3-3 proteins, particularly of the epsilon isoform, are detectable in cerebrospinal fluids of cerebellar diseases in children. ( 23078967 )
2013
30
Balance rehabilitation therapy by tongue electrotactile biofeedback in patients with degenerative cerebellar disease. ( 23232167 )
2012
31
Dichotic listening test in patients with chronic cerebellar disease. ( 22133971 )
2012
32
Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. ( 22140200 )
2012
33
Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. ( 22072678 )
2011
34
Vestibulo-cerebellar disease impairs the central representation of self-orientation. ( 21431098 )
2011
35
Effects of cerebellar disease on sequences of rapid eye movements. ( 21385592 )
2011
36
Spike removal through multiscale wavelet and entropy analysis of ocular motor noise: a case study in patients with cerebellar disease. ( 21262262 )
2011
37
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. ( 21157217 )
2011
38
Long-term effects of coordinative training in degenerative cerebellar disease. ( 20737551 )
2010
39
Longitudinal tracking of gait and balance impairments in cerebellar disease. ( 20544808 )
2010
40
Aphasia and neglect are uncommon in cerebellar disease: negative findings in a prospective study in acute cerebellar stroke. ( 20680538 )
2010
41
Intensive coordinative training improves motor performance in degenerative cerebellar disease. ( 19864636 )
2009
42
Time estimation in Parkinson's disease and degenerative cerebellar disease. ( 18580578 )
2008
43
Clinical manifestation of focal cerebellar disease as related to the organization of neural pathways. ( 18439215 )
2008
44
Reduced saccadic resilience and impaired saccadic adaptation due to cerebellar disease. ( 18184318 )
2008
45
Pediatric periodic alternating gaze deviation with midline cerebellar disease. ( 17280848 )
2007
46
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. ( 17404205 )
2007
47
Clinical symptoms of cerebellar disease and their interpretation. ( 18041661 )
2007
48
Commentary on 'Holmes G. Clinical symptoms of cerebellar disease and their interpretation. Lecture I. The Lancet 1922;202 (Vol. 1 for 1922):1178-1182, and Holmes G. Clinical symptoms of cerebellar disease and their interpretation. Lecture II. The Lancet 1922;202 (Vol. 1 for 1922):1232-1237'. ( 17566248 )
2007
49
The Croonian Lectures on the clinical symptoms of cerebellar disease and their interpretation. Lecture II. 1922. ( 17566247 )
2007
50
The Croonian Lectures On The Clinical Symptoms Of Cerebellar Disease And Their Interpretation. Lecture I. 1922. ( 17510914 )
2007

Variations for Cerebellar Disease

Expression for Cerebellar Disease

Search GEO for disease gene expression data for Cerebellar Disease.

Pathways for Cerebellar Disease

GO Terms for Cerebellar Disease

Cellular components related to Cerebellar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.8 APTX ATM ATXN3 ATXN7 ITPR1 NOP56
2 presynapse GO:0098793 9.58 ATP2B3 CACNA1A SPTBN2
3 dendrite GO:0030425 9.55 ATXN10 CACNA1A CALB1 PRKCG SACS
4 cytoplasm GO:0005737 9.47 ZIC1 SPTBN2 APTX ATM ATXN10 ATXN3
5 calyx of Held GO:0044305 9.43 CALB1 PRKCG
6 postsynaptic cytosol GO:0099524 9.37 CALB1 PRKCG
7 neuronal cell body GO:0043025 9.35 ATXN10 ATP1A3 CACNA1A CALB1 SPTBN2
8 presynaptic cytosol GO:0099523 9.32 CALB1 PRKCG

Biological processes related to Cerebellar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion transmembrane transport GO:0070588 9.43 ATP2B3 CACNA1A ITPR1
2 response to pain GO:0048265 9.16 PRKCG CACNA1A
3 regulation of presynaptic cytosolic calcium ion concentration GO:0099509 8.96 CALB1 ATP2B3
4 regulation of postsynaptic cytosolic calcium ion concentration GO:0099566 8.62 CALB1 ITPR1

Molecular functions related to Cerebellar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion transmembrane transporter activity GO:0015085 8.62 ATP2B3 ITPR1

Sources for Cerebellar Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....